Solid dosage formulations of an orexin receptor antagonist
US11980623B2 · kind B2 · utility
0Cited by
9References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 14, 2021 |
| Grant date | May 14, 2024 |
| Priority date | — |
| Expiry date | Sep 14, 2041 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to a pharmaceutical composition comprising the compound suvorexant, or a pharmaceutically acceptable salt thereof, a concentration-enhancing polymer, and optionally a pharmaceutically acceptable surfactant.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.